← All trials
NCT04592419
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2020
- Primary completion
- Apr 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- Oct 19, 2020
- Last posted
- Oct 19, 2020
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Kodiak Sciences IncLead sponsor
- Kodiak Sciences IncStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.